News

QURE

uniQure (QURE): Gene Therapy Progress in Hemophilia B

Edward Kim | Equities.com |

Targeting hemophilia B, Huntington's disease and (in partnership with BMY) cardiovascular disease.


12 IPOs Planned for February 3 Week

Francis Gaskins | Equities.com |

The full IPO calendar is available at IPOpremium.com Ranked by size of IPO, largest first. (1) Real estate finance Based in New York, NY, Ladder Capital ($LADR) scheduled a $225 million IPO on the


IPO Report: uniQure (QURE)

Francis Gaskins | Equities.com |

uniQure (QURE) is a leader in the field of gene therapy and has developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. 13 other


Sponsored Financial Content

Market Movers